Eli Lilly is investing heavily to scale up its Zepbound supply chain, building new active pharmaceutical ingredient (API) facilities to eliminate persistent shortages of the blockbuster weight-loss drug.

Manufacturing Scale

The massive capital expenditure aims to capture the full addressable market for obesity treatments, ensuring that patients and pharmacies can reliably access the medication without backorders.